Lower serum concentrations of CXCL8 and CXCL10 in RRMS patients and decreased peripheral production of CXCL8 in relapse may indicate compensatory anti-inflammatory counter-regulation in MS. This evidence concerns the gene CXCL10 and relapsing-remitting multiple sclerosis.